



Biocon Limited

20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

Date of submission: July 8, 2019

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON
---	---

Dear Sir/Madam,

Sub: Pre -Approval U.S. FDA Inspection Conducted at Biocon's Insulins Facilities in Malaysia

Ref: Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

"This is to inform you that Biocon Sdn Bhd's Insulin Glargine Drug Substance, Drug Product and Device assembly facilities in Malaysia underwent a pre-approval inspection by the U.S. FDA between June 24 and July 5, 2019. The inspection across these 3 units concluded with 12 observations issued on the Form 483.

We will respond to the FDA with a Corrective and Preventive Action Plan and are confident of addressing these observations expeditiously. We do not expect any change to our commercialization plans for Insulin glargine in the U.S. Biocon remains committed to global standards of Quality and Compliance."
- Company Spokesperson

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,
Yours faithfully

For Biocon Limited

Siddharth Mittal
Chief Financial Officer & Compliance Officer